ArticleCureus2022
Nonatopic Eosinophilic Esophagitis in an Adult.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic esophagitis (EoE) is an inflammatory condition limited to the esophagus, predominantly consisting of eosinophils, and triggered by hypersensitivity reactions. Recurrent dysphagia secondary to EoE is uncommon in patients with no history of asthma and/or atopic conditions. We are presenting a case of a 48-year-old male suffering from dysphagia for 10 years that worsened over a six-month period. The patient reported no known food and drug allergies, asthma, and other atopic conditions. On esophagogastroduodenoscopy (EGD), the patient fulfilled all five endoscopic reference score (EREFS) criteria, granting a final diagnosis of eosinophilic esophagitis with a score of 6. Biopsy confirmed eosinophilic esophagitis, revealing 20 eosinophils/high-power fields. Skin prick testing was negative. His symptoms had improved at the office follow-up after three weeks after esophageal dilation and proton pump inhibitor (PPI) but did not completely resolve. The patient was then started on fluticasone 440 mcg two times a day. After eight weeks, the patient was symptom-free by taking dual therapy of PPI and fluticasone. The patient was advised to continue taking the daily PPI and then a six-week course of fluticasone if he experienced an exacerbation in his symptoms. In this report, symptom improvement with esophageal dilation, PPI, and fluticasone suggested a successful treatment regimen for EoE in the setting of no known atopy in our patient. Our case highlights EoE in an adult with no known asthma and allergies. The report identifies the importance of a prompt clinical diagnosis and appropriate combination treatment due to the progressive pain and its worsening associated with eosinophilic esophagitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.